Evidence map›Paper›PMID 42162231›Full record

ArticleNPJ precision oncology2026

KRAS and BRAF mutations modify adjuvant chemotherapy outcomes in early stage colorectal cancer.

Durgesh Wankhede, Mary Jose Urruchua Rodriguez, Dominic Edelmann, Matthias Kloor, Hendrik Bläker, Alexander Brobeil, Wilfried Roth, Hermann Brenner, Michael Hoffmeister

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Durgesh WankhedeDivision of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Mary Jose Urruchua RodriguezDivision of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Dominic EdelmannDepartment of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Matthias KloorDepartment of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Hendrik BläkerDepartment of General Pathology, Institute of Pathology, Charité University Medicine Hospital, Berlin, Germany.
Alexander BrobeilNational Center for Tumour Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Wilfried RothInstitute of Pathology, University Medical Center Mainz, Mainz, Germany.
Hermann BrennerCancer Prevention Graduate School, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael HoffmeisterDivision of Clinical Epidemiology of Early Cancer Detection, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.hoffmeister@dkfz.de.

Funding

Bundesministerium für Forschung, Technologie und Raumfahrt 01KH0404, 01ER0814, 01ER0815, 01ER1505A, 01ER1505B, 01KD2104ADeutsche Forschungsgemeinschaft BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HO 5117/2-2, HE 5998/2-1, HE 5998/2-2, KL 2354/3-1, KL 2354 3-2, RO 2270/8-1, RO 2270/8-2, BR 1704/17-1, BR 1704/17-2
6 · The paper itself

Abstract

KRAS and BRAF

Identifiers

PMID42162231
PMCPMC13190747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.